Amedeo's Top 20

Amedeo Smart

Independent Medical Education


08 June 2020

Multidisciplinary Journal Club

  1. Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, et al.
    Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
    Lancet 2020;395:1487-1495.

  1. Ju B, Zhang Q, Ge J, Wang R, et al.
    Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Nature 2020.

  2. Sternberg CN, Fizazi K, Saad F, Shore ND, et al.
    Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med 2020.

  3. Samama CM, Laporte S, Rosencher N, Girard P, et al.
    Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    N Engl J Med 2020;382:1916-1925.

  4. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, et al.
    Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Lancet 2020.

  1. Shore ND, Saad F, Cookson MS, George DJ, et al.
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    N Engl J Med 2020.

  2. Lin NU, Borges V, Anders C, Murthy RK, et al.
    Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    J Clin Oncol 2020.

  3. Sheppard JP, Burt J, Lown M, Temple E, et al.
    Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial.
    JAMA 2020;323:2039-2051.

  4. Paik PK, Felip E, Veillon R, Sakai H, et al.
    Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
    N Engl J Med 2020.

  5. Turner RS, Hebron ML, Lawler A, Mundel EE, et al.
    Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
    Ann Neurol 2020.

  1. Benton DJ, Gamblin SJ, Rosenthal PB, Skehel JJ, et al.
    Structural transitions in influenza haemagglutinin at membrane fusion pH.
    Nature 2020.

  2. Rudin CM, Awad MM, Navarro A, Gottfried M, et al.
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol 2020.

  3. Heinzel S, Aho VTE, Suenkel U, von Thaler AK, et al.
    Gut microbiome signatures of risk and prodromal markers of Parkinson's disease.
    Ann Neurol 2020.

  4. Fantini ML, Fedler J, Pereira B, Weintraub D, et al.
    Is RBD a risk factor for impulse control disorder in Parkinson's disease?
    Ann Neurol 2020.

  5. Reck M, Wehler T, Orlandi F, Nogami N, et al.
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol 2020.

  1. Solling AS, Harslof T, Langdahl B.
    Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial.
    J Bone Miner Res 2020.

  2. Hindiyeh NA, Zhang N, Farrar M, Banerjee P, et al.
    The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review.
    Headache 2020.

  3. Guo X, Zhu Y, Hong Y.
    Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis.
    Hypertension 2020.

  4. Kanellopoulos A, Ahmed MZ, Kishore B, Lovell R, et al.
    Covid-19 in Bone Marrow Transplant Recipients: Reflecting on a Single Centre Experience.
    Br J Haematol 2020.

  5. Kao WY, Su CW, Tan EC, Lee PC, et al.
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology 2018.


more..


Privacy Policy